Marker Therapeutics, Inc. (MRKR) › Total AssetsMarker Therapeutics, Inc. (MRKR) — Total AssetsAnnual figures by period end, from SEC filings.2010-12-31: $116.4K2011-12-31: $307.9K2012-12-31: $87.4K2013-12-31: $77.0K2015-12-31: $6.65M2016-12-31: $7.92M2017-12-31: $5.18M2018-12-31: $62.14M2019-12-31: $46.36M2020-12-31: $45.61M2021-12-31: $68.14M2022-12-31: $34.42M2023-12-31: $17.13M2024-12-31: $22.02M2025-12-31: $19.07M$19.07M2010-12-31Total Assets (USD)2025-12-31Period endedTotal AssetsChange YoYSource filing2025-12-31$19.07M-13.4%2026-03-18Balance as of period end2024-12-31$22.02M+28.6%2026-03-18Balance as of period end2023-12-31$17.13M-50.2%2025-03-31Balance as of period end2022-12-31$34.42M-49.5%2024-03-26Balance as of period end2021-12-31$68.14M+49.4%2023-03-22Balance as of period end2020-12-31$45.61M-1.6%2022-03-17Balance as of period end2019-12-31$46.36M-25.4%2021-03-09Balance as of period end2018-12-31$62.14M+1099.6%2020-03-12Balance as of period end2017-12-31$5.18M-34.6%2019-03-15Balance as of period end2016-12-31$7.92M+19.2%2018-03-23Balance as of period end2015-12-31$6.65M—2017-03-14Balance as of period end2013-12-31$77.0K-11.8%2014-04-17Balance as of period end2012-12-31$87.4K-71.6%2014-04-17Balance as of period end2011-12-31$307.9K+164.5%2013-05-15Balance as of period end2010-12-31$116.4K—2012-04-16Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)